戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 benefit for combination therapy (banding and sclerotherapy).
2    None of the patients previously underwent sclerotherapy.
3 er laser ablation or surgery than after foam sclerotherapy.
4 ar veins within 60 days after treatment with sclerotherapy.
5 th saphenous vein insufficiency treated with sclerotherapy.
6 ation of transvenous embolization and hybrid sclerotherapy.
7  an unusual but not rare complication of STS sclerotherapy.
8 t potentially serious complication of venous sclerotherapy.
9 aphenous vein at 7-21 days after polidocanol sclerotherapy.
10 ding has been shown to be superior to needle sclerotherapy.
11 osts and lower recurrent bleeding rates than sclerotherapy.
12 ymphoceles; five of these patients underwent sclerotherapy.
13 phageal varies, TIPS was more effective than sclerotherapy.
14 ctive variceal hemorrhage despite endoscopic sclerotherapy.
15  to -1.22; P<0.001; and for surgery vs. foam sclerotherapy, -2.60; 95% CI, -3.99 to -1.22; P<0.001).
16  between groups] for laser ablation vs. foam sclerotherapy, -2.86; 95% confidence interval [CI], -4.4
17 m esophageal varices than patients receiving sclerotherapy (3 of 24 compared with 12 of 25; P = 0.012
18                               Despite urgent sclerotherapy, active variceal hemorrhage has a 70%-90%
19                    Experts in using specific sclerotherapy agents (sodium tetradecyl sulfate and poli
20 he treatment of choice for most VMs, but all sclerotherapy agents are associated with the risk of com
21 hi protocol was used to achieve consensus on sclerotherapy among a panel of 6 experts.
22           No significant differences between sclerotherapy and cyanoacrylate groups regarding rebleed
23  head and neck, including medical therapies, sclerotherapy and embolization procedures, and surgery.
24 ness analysis comparing TIPS with endoscopic sclerotherapy and endoscopic ligation for the prevention
25                       Ultrasound-guided foam sclerotherapy and endovenous laser ablation are widely u
26 t per bleed prevented for TIPS compared with sclerotherapy and ligation was $8,803 and $12, 660, resp
27 e removal, one patient received percutaneous sclerotherapy and one patient received a combination of
28 uidance and monitoring of minimally invasive sclerotherapy and permits verification of therapeutic su
29 us and hybrid (endoscopy-guided angiography) sclerotherapy and procedural complications (according to
30         In a two-way comparison between foam sclerotherapy and surgery, 54.5% of the model iterations
31                                   Endoscopic sclerotherapy and TIPS are equivalent with respect to re
32 8%) and 21 (40.4%) of patients had injection sclerotherapy and variceal band ligation, respectively.
33 n age, 22 mo) underwent primary prophylaxis (sclerotherapy and/or banding, depending on age and weigh
34 iceal bleeding prophylaxis with propranolol, sclerotherapy, and shunt surgery in cirrhotic patients s
35 ompared the outcomes of laser ablation, foam sclerotherapy, and surgery.
36      Percutaneous or endoscopy-guided hybrid sclerotherapy appeared to be a safe and effective altern
37 us laser ablation and ultrasound-guided foam sclerotherapy are recommended alternatives to surgery fo
38 lacebo (among patients that received initial sclerotherapy/banding before randomization) (RR, 0.46; 9
39                        Our results show that sclerotherapy combined with ligation offers no benefit o
40                                 Status after sclerotherapy constitutes a good clinical model for veno
41                           Thus, percutaneous sclerotherapy could potentially have a promising result
42                       Combined ligation plus sclerotherapy does not reduce the number of treatment se
43  The study included 60 patients subjected to sclerotherapy due to venous insufficiency (45 women and
44  BEV were randomized to emergency endoscopic sclerotherapy (EEST) (n=106) or EPCS (n=105).
45  surgery than among those who underwent foam sclerotherapy (effect size [adjusted differences between
46                         Endoscopic injection sclerotherapy (EIS) is a life-saving procedure for pedia
47                            Today, endoscopic sclerotherapy (ES) and endoscopic ligation (EL) are the
48 s were performed emergently after endoscopic sclerotherapy failed to stop active bleeding.
49 t (82% distal splenorenal shunts) because of sclerotherapy failure or because endoscopic treatment wa
50 Recurrent variceal hemorrhage was managed by sclerotherapy followed by angiographic assessment of TIP
51 reotide had comparable efficacy to immediate sclerotherapy for control of bleeding (RR, 0.94; 95% CI,
52 re than 10 years of experience in the use of sclerotherapy for HHT-associated epistaxis and cutaneous
53 h cyanoacrylate injection may be superior to sclerotherapy for initial control of active bleeding.
54 treating TN include ethanol ablation for TN; sclerotherapy for thyroid cysts; and thermal techniques,
55 ter sclerotherapy was the most common in the sclerotherapy group (n = 10).
56 ollow-up (+/-SE) was 567 +/- 104 days in the sclerotherapy group and 575 +/- 109 days in the TIPS gro
57 e (9 patients in the TIPS group and 8 in the sclerotherapy group), portal gastropathy (1 patient in e
58 g (5 patients in the TIPS group and 3 in the sclerotherapy group), sepsis (3 and 2 patients, respecti
59 he stents (TIPS group) or crossover to TIPS (sclerotherapy group).
60 significantly higher in cyanoacrylate versus sclerotherapy groups (98.25, 83.93% respectively, P = 0.
61                Patients assigned to repeated sclerotherapy had the procedure weekly.
62                       The patients underwent sclerotherapy in a single intervention with either 0.2%
63 me required for minimally invasive MR-guided sclerotherapy in regression analysis, (d) ability of MR
64                                              Sclerotherapy involves injecting a sclerosing agent into
65                      Conclusion Percutaneous sclerotherapy is a safe and feasible method with promisi
66                                   Ambulatory sclerotherapy is a safe, viable alternative to conventio
67                                              Sclerotherapy is the treatment of choice for most VMs, b
68                                     Although sclerotherapy is the treatment of choice for reticular v
69       The total annual costs per patient for sclerotherapy, ligation, and TIPS were $23,459, $23,111,
70         The number of bleeds per patient for sclerotherapy, ligation, and TIPS would be 0.39, 0.32, a
71 opic sclerotherapy who received prophylactic sclerotherapy, ligation, or TIPS over 1 year.
72                                     However, sclerotherapy may be superior to TIPS with respect to su
73  the age of venous thrombosis in polidocanol sclerotherapy model.
74              Since the first reports on foam sclerotherapy, multiple studies have been conducted to d
75                        A standard endoscopic sclerotherapy needle and sheath filled with 0.9% saline
76 x patients underwent endoscopy-guided hybrid sclerotherapy, one patient underwent endoscopic tissue r
77 otocol using octreotide or terlipressin with sclerotherapy or band ligation for active bleeding at en
78  bleeding varices not amenable to endoscopic sclerotherapy or banding were prospectively randomized t
79     They were randomly treated by endoscopic sclerotherapy or cyanoacrylate injection as banding was
80 ifestyle changes) to minimally invasive (eg, sclerotherapy or endoluminal ablation), invasive (surgic
81 t per bleed prevented for TIPS compared with sclerotherapy or ligation was sensitive to the cost of T
82 completed with either ultrasound-guided foam sclerotherapy or local anesthetic phlebectomy.
83 nomalies who underwent ethanol embolization, sclerotherapy, or both.
84 ophylaxis with endoscopic variceal ligation, sclerotherapy, or nonspecific beta-blockade in children
85 er jejunal feeding tubes, stent perforation, sclerotherapy, or surgical or endoscopic trauma.
86 re obliterated more reliably by TIPS than by sclerotherapy (P < 0.001).
87 children had undergone at least one previous sclerotherapy procedure.
88  for this retrospective review, in which 647 sclerotherapy procedures were performed in 204 patients
89                        Fourteen percutaneous sclerotherapy procedures with magnetic resonance (MR) im
90                                    In-office sclerotherapy provides several advantages, including qui
91 he patients had TIPS placed for acute (2) or sclerotherapy-resistant (3) variceal hemorrhage.
92 ed 7 +/- 1, 14 +/- 2, and 21 +/- 2 days post-sclerotherapy, respectively.
93                  Thus, combined ligation and sclerotherapy should not be used to treat patients with
94                                     Standard sclerotherapy techniques were used.
95 r options to manage acute bleeding episodes (sclerotherapy, TIPS) and advanced liver disease complica
96                     Seventy-six percutaneous sclerotherapy treatments were performed by one radiologi
97 ers and receiving microsclerotherapy or foam sclerotherapy treatments, being unwilling to enter into
98 nducted to assess the safety and efficacy of sclerotherapy versus cyanoacrylate injection for managem
99                                 In addition, sclerotherapy was not performed so as to avoid an unnece
100                                 Percutaneous sclerotherapy was performed successfully and without com
101                                 Percutaneous sclerotherapy was performed using a mixture of bleomycin
102                                              Sclerotherapy was performed with bleomycin when daily dr
103                                   Endoscopic sclerotherapy was preferred for more than a decade, but
104                                              Sclerotherapy was significantly less cost-effective than
105 PS group (n = 12), and pain developing after sclerotherapy was the most common in the sclerotherapy g
106 hageal or contiguous gastric varices despite sclerotherapy were assessed for risk of dying after emer
107 al ablation) and other options, such as foam sclerotherapy, which can be used in all types of varices
108                                              Sclerotherapy, which induces fibrosis with a sclerosant
109 esophageal variceal bleeding with endoscopic sclerotherapy who received prophylactic sclerotherapy, l
110 ned to study whether combining ligation with sclerotherapy will allow quicker eradication of varices
111                                              Sclerotherapy with 0.2% polidocanol diluted in 70% HG wa
112                                              Sclerotherapy with 0.2% polidocanol plus 70% HG was sign
113                      Background Percutaneous sclerotherapy with bleomycin has been proven to have a p
114 bility, efficacy, and safety of percutaneous sclerotherapy with bleomycin in the management of sympto
115 erformed comparing combination ligation plus sclerotherapy with ligation alone in patients with major
116                         Combining endoscopic sclerotherapy with ligation has been proposed to hasten
117                               In conclusion, sclerotherapy with MR imaging guidance can be performed
118 at stable patients with HHT are eligible for sclerotherapy, with individualized precautions based on

 
Page Top